| Organization / Website | Specialty Area | Purpose | Award / Deadline |
National Cancer Institute (NCI) |
Cancer | This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical). | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR) |
Embryonic Lethal Knockout (KO) Mouse Strains | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The KOMP2 KO mouse phenotyping effort has generated 2,500 mouse strains with plans to generate an additional 6,000 over the next five years. Overall, the IMPC hopes to achieve broad-based phenotyping of 20,000 KO strains. About 30% of these strains either are or are expected to be embryonic or perinatal lethal or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in depth phenotyping and research. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Budgets with direct costs of up to $499,999 per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: June 5, 2017 (new) and July 5, 2017 (renewal, resubmission, revision); October 5, 2017 (new) and November 5, 2017 (renewal, resubmission, revision); June 5, 2018 (new) and July 5, 2018 (renewal, resubmission, revision); October 5, 2018 (new) and November 5, 2018 (renewal, resubmission, revision); June 5, 2019 (new) and July 5, 2019 (renewal, resubmission, revision); October 5, 2019 (new) and November 5, 2019 (renewal, resubmission, revision), by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Clinical Interventional Trials relevant to NIAMS mission | This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to permit the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant is recommended prior to submission of an application through a U01 clinical trial implementation application that will support the actual implementation and conduct of the study. The planning should be intended to support trials that are hypothesis-driven, milestone-defined, and have the potential for high impact within the research mission of the NIAMS. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $300,000 in direct costs over a period of two years. The amount of support requested should reflect the actual needs of the proposed project. The maximum project period is two years. Date: March 1, 2017; July 3, 2017; November 1, 2017; March 2, 2018; July 2, 2018; November 1, 2018; March 1, 2019; July 1, 2019; November 1, 2019, by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Clinical Interventional Trials relevant to NIAMS mission | This Funding Opportunity Announcement (FOA) invites cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without having applied for a R34. The NIAMS expects such trials to be hypothesis driven, milestone-defined, and have the potential for high impact within the research mission of the NIAMS. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The project period may not exceed five years. Date: March 1, 2017; July 3, 2017; November 1, 2017; March 2, 2018; July 2, 2018; November 1, 2018; March 1, 2019; July 1, 2019;November 1, 2019, by 5:00 PM |
National Institute of Allergy and Infectious Diseases (NIAID) |
AIDS Prophylactic Vaccine Discovery Research | The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive modeling of vaccine concepts in non-human primates may be included. | NIH intends to fund an estimate of 1-2 awards, corresponding to a total of $4M, for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets are limited to $2.5M/year in direct costs and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years. Date: March 13, 2018; March 13, 2019; March 13, 2020 , by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Digestive and Liver Diseases | This Funding Opportunity Announcement (FOA) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding. | NIH intends to fund an estimate of 1-2 awards, corresponding to a total of $4M, for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets are limited to $2.5M/year in direct costs and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.NIDDK intends to commit $2.4 million in FY 2018 to fund 2 awards and $3.6 million in FY 2019 to fund 3 awards. Application budgets are limited to $750,000 direct costs per year, exclusive of any consortium/contractual facilities and administrative (F&A) costs but need to reflect the actual needs of the proposed project. The project period for an application submitted to this funding opportunity may not exceed five years. Date: March 13, 2018; March 13, 2019; March 13, 2020 , by 5:00 PM |
| Investigator-Initiated Clinical Trials | This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The application should propose the developmental work to be performed that would enhance the probability of reaching definitive outcomes in a clinical trial. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $150,000 direct costs. The scope of the proposed project should determine the project period. The maximum period is one year. Date: March 24, 2017, July 24, 2017, November 24, 2017, March 23, 2018, July 24, 2018, November 26, 2018, March 25, 2019, July 24, 2019, November 25, 2019, by 5:00 PM |
|
National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA), National Institute of General Medical Sciences (NIGMS) |
Clinical Trials | This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period of 6 or 7 years. Date: March 7, 2017; December 7, 2017; March 7, 2018; December 7, 2018; March 7, 2019; December 6, 2019, by 5:00 PM |
National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), Office of Behavioral and Social Sciences Research (OBSSR) |
Native American (NA) Health | The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in a single year. The scope of the proposed project should determine the project period. The total project period may not exceed 2 years. Date: May 14, 2018; May 14, 2019; May 14, 2020, by 5:00 PM |
National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), Office of Behavioral and Social Sciences Research (OBSSR) |
Native American (NA) Health | The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities. Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period may not exceed 5 years. Date: May 14, 2018; May 14, 2019; May 14, 2020, by 5:00 PM |
National Cancer Institute (NCI) |
Quantitative Imaging (QI) Software Tools, Cancer Therapies | This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets need to reflect the actual needs of the proposed project but must not exceed $300,000 in direct costs for each year of the UG3 phase and $500,000 (direct costs) for each year of the UH3 phase. The proposed project period for the initial development phase (UG3) award may not exceed 2 years. The total UG3/UH3 period of performance may not to exceed 5 years. Date: May 9, 2017; September 12, 2017; January 9, 2018; May 9, 2018; September 12, 2018; January 9, 2019; May 9, 2019; September 12, 2019; January 9, 2020, by 5:00 PM |
National Cancer Institute (NCI) |
Quantitative Imaging (QI) Software Tools, Cancer Therapies | This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets need to reflect the actual needs of the proposed project but must not exceed $500,000 (direct costs) for each proposed year. The maximum project period is 5 years. Date: May 9, 2017; September 12, 2017; January 9, 2018; May 9, 2018; September 12, 2018; January 9, 2019; May 9, 2019; September 12, 2019; January 9, 2020, by 5:00 PM |
This Funding Opportunity Announcement (FOA) is developed as a Common Fund Initiative through the NIH Office of the NIH Director, Office of Strategic Coordination. The FOA will be administered by the National Center for Advancing Translational Sciences (NCATS) on behalf of the NIH. |
Control of Organ Function by the Peripheral Nervous System | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications (via limited competition) for SPARC Technologies to Understand the Control of Organ Function by the Peripheral Nervous System. This NIH Funding Opportunity Announcement (FOA) solicits applications to develop new and/or enhance existing tools and technologies to facilitate the progress of other components of the SPARC program. The scope encompasses a wide range of capabilities, spanning the fields of photonics, systems engineering, virology and genomics, device design and manufacture, surface chemistry, tissue engineering, neural interfacing, biomarker sensing, and more. The specific tools and technology priorities will vary for each receipt date listed in the companion OT1 pre-application funding opportunity (See RM-17-009 and https://commonfund.nih.gov/sparc/FOApriorities). | NIH anticipates funding up to 20 awards through this FOA, corresponding to a total of approximately $10M in total costs in 2017, $6M in 2018 and $4M in 2019. While there is no limit, awards resulting from this FOA are expected to range between $250,000 and $5,000,000 direct costs per year. Awards are expected to be three years or less in duration, with the opportunity for additional funding. Date: New and resubmission applications are accepted on the date specified in the Invitation to Submit after successful competition of the corresponding OT1 pre-application (See RM-17-009) and must be submitted by 5:00 PM local time of the applicant. |
Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH) |
Multi-Level Physical Activity Intervention Programs | The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. | NIH anticipates funding up to 20 awards through this FOA, corresponding to a total of approximately $10M in total costs in 2017, $6M in 2018 and $4M in 2019. While there is no limit, awards resulting from this FOA are expected to range between $250,000 and $5,000,000 direct costs per year. Awards are expected to be three years or less in duration, with the opportunity for additional funding. Date: New applications: February 16, 2018; October 16, 2018; June 16, 2019; February 16, 2020; October 16, 2020, by 5:00 PM local time of applicant organization. Resubmission applications: March 16, 2018; November 16, 2018; July 16, 2019; March 16, 2020; November 16, 2020, by 5:00 PM |
National Heart, Lung, and Blood Institute (NHLBI) |
Biomedical or Biobehavioral Research relevant to NHLBI | The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection; it will not support the collection of new data. | The R21 phase may not exceed $275,000 in direct costs for the 2-year project period, with no more than $200,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed $750,000 in direct costs for the 3-year project period, with no more than $250,000 in direct costs in any single year of the R33 phase. The scope of the proposed project should determine the project period. The maximum period of the combined R21 and R33 phases is 5 years, with up to 2 years for the R21 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible. Date: New applications: February 24, 2017; February 23, 2018; February 22, 2019, by 5:00 PM; Resubmission Applications: October 30, 2017; October 30, 2018; October 30, 2019, by 5:00 PM |
Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH) |
Multi-Level Physical Activity Intervention Programs | The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NHLBI intends to fund up to ten awards per year. Direct costs must be limited to $150,000 over a R21 two-year period, with no more than $75,000 in direct costs allowed in any single year. Applications exceeding this amount will not be reviewed. The total project period may not exceed 2 years. Date: New applications: February 5, 2018; October 5, 2018; June 5, 2019; February 5, 2020; October 5, 2020, by 5:00 PM local time of applicant organization. Resubmission applications: March 5, 2018; November 5, 2018; July 5, 2019; March 5, 2020; November 5, 2020, by 5:00 PM |
Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH) |
Multi-Level Physical Activity Intervention Programs | The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: New applications: February 5, 2018; October 5, 2018; June 5, 2019; February 5, 2020; October 5, 2020, by 5:00 PM. Resubmission applications: March 5, 2018; November 5, 2018; July 5, 2019; March 5, 2020; November 5, 2020, by 5:00 PM. |
National Cancer Institute (NCI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Imaging or Spectroscopic Technologies, Cancer Biology | The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status. A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem. The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: New Dates March 1, 2017; June 7, 2017; October 3, 2017; March 1, 2018; June 7, 2018; October 3, 2018; March 1, 2019; June 7, 2019; October 3, 2019, by 5:00 PM |
National Institute of General Medical Sciences (NIGMS)
|
Biomedical Sciences: Cell Biology, Biophysics, Genetics, Developmental Biology, Pharmacology, Physiology, Biological Chemistry, Computational Biology, Technology Development and Bioinformatics | The NIGMS Postdoctoral Research Associate (PRAT) Program’s overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences, in NIH intramural research laboratories, to a diverse group of postdoctoral fellows to prepare them for leadership positions in biomedical careers. The research projects proposed should focus on NIGMS mission-related areas of basic biomedical science. These include cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, computational biology, technology development and bioinformatics. Studies employing model organisms are encouraged. The PRAT Program distinguishes itself by providing, in addition to the laboratory research experience, a structured training environment with extensive career development and networking opportunities planned and supported by this program. |
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Fellowship budgets are composed of stipends and travel allowance. Postdoctoral fellows may receive up to 3 years of support from the NIGMS PRAT fellowship. Date: October 3, 2016; October 3, 2017; October 3, 2018, by 5:00 P.M. |
National Institute of Neurological Disorders and Stroke (NINDS) |
Administrative Supplements | This Funding Opportunity Announcement (FOA) encourages administrative supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25, PAR-13-384 and subsequent reissuances) | The NINDS intends to fund approximately 30-50 participants across the entire R25 program in FY2018. The direct cost of each supplement award is capped at 80% of the appropriate PGY salary for the requested participant for the duration of support between July 1 and June 30 of the fiscal year in which support is requested, plus associated fringe benefits, plus $2,000 for travel to meetings plus $1,000 for travel to an NINDS R25 workshop. If the participant is simultaneously enrolled in a PHD-granting program, up to $12,800 may also be requested for costs associated with research activities associated with both R25 participation and the degree-granting program. The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes. Date: October 31, 2017, October 31, 2018, October 31, 2019 by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
October 31, 2017; March 2, 2018; June 29, 2018; October 30, 2018; March 1, 2019; June 28, 2019; October 31, 2019; March 3, 2020; and June 30, 2020, by 5:00 PM | The NIDDK Central Repositories house valuable samples and data from numerous major clinical studies. This FOA allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at www.niddkrepository.org. Applicants must provide information from the NIDDK Central Repositories documenting sample availability. | Funds are not awarded via the X01 mechanism. The maximum project period is 5 years. Date: October 31, 2017; March 2, 2018; June 29, 2018; October 30, 2018; March 1, 2019; June 28, 2019; October 31, 2019; March 3, 2020; and June 30, 2020, by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI), National Institute of Nursing Research (NINR) |
Research Activities for Early Stage Careers of Independent Clinical Researchers | The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility. | For the transition award (R00), applicants can request direct costs of up to $499,000 per year. This amount includes salaries, fringe benefits, and research costs. Indirect costs will be reimbursed at the extramural sponsoring institution’s indirect cost rate. The R00 transition award is for up to 5 years. Date: Rolling receipt dates: September 25, 2017 - January 7, 2018; January 25, 2018 - May 7, 2018; May 25, 2018 - September 7, 2018; September 25, 2018 - January 7, 2019; January 25, 2019 - May 7, 2018; May 25, 2019 - September 7, 2019; September 25, 2019 - January 7, 2020; January 25, 2020 - May 7, 2020; , by 5:00 PM |
National Institute on Drug Abuse (NIDA) |
Drug Abuse and Addiction | NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to drug abuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators , and share findings, data and their resources, consistent with achieving the goals of the program. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: September 26, 2017; September 26, 2018, September 26, 2019, by 5:00 PM |
National Institute of Mental Health (NIMH) |
Mentored Research Supporting Career Trajectory Towards Independent Research in the Mental Health of HIV/AIDS. | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Mental Health (NIMH) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs and advance the priorities outlined in the Office of AIDS Research (OAR) Annual Strategic Plan and the research program priorities of the NIMH Division of AIDS Research (DAR). To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities that either capitalize on existing networks of collaborating investigators or develop institute-based research education programs. Both research experiences and mentoring activities are required; research experiences are expected to be primary. Research Education Programs are expected to enhance the professional development of the participants and foster a career trajectory towards independent research in the mental health of HIV/AIDS. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application may not exceed five years. Date: September 7, 2018; September 7, 2019; September 7, 2020, by 5:00 PM |
National Institute on Deafness and Other Communication Disorders (NIDCD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Language/Literacy Development of Dual Language Learners (DLLs) in USA | The purpose of this FOA is to support investigator-initiated R01 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: Standard dates apply by 5:00 PM |
National Institute on Deafness and Other Communication Disorders (NIDCD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Language/Literacy Development of Dual Language Learners (DLLs) in USA | The purpose of this FOA is to support investigator-initiated R21 applications that will inform our understanding of the typical and atypical patterns of language and literacy development of dual language learners (DLLs) in the United States. Applicants are encouraged to take advantage of advances in the language sciences and related fields to identify and clarify specific cognitive, linguistic, neurobiological, and sociocultural factors associated with normal and impaired language and literacy acquisition in young DLL populations | The combined budget for direct costs for the two-year project period may not exceed $275,000 No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: Standard dates apply by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Clinical Trials relevant to NIDDK mission | This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to be conducted at no more than two clinical research centers. NIDDK is committed to improving the health of people with diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic and hematologic diseases. Applications for clinical trials submitted under this FOA should be hypothesis driven, have clearly described aims and objectives, and have a high likelihood that the trial findings will improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years. Date: Standard dates apply by 5:00 PM |
National Center for Advancing Translational Sciences (NCATS) |
Clinical Studies to Repurpose Existing Drugs or Biologics (Therapeutics) | This Funding Opportunity Announcement (FOA) invites applications for support of clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase l trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/therapeutics/current, http://openinnovation.astrazeneca.com/, or any website that lists experimental drugs or biologics), or computational algorithms. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition. The U01 award may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use. | Application budgets need to reflect the actual needs of the proposed project. In a disease agnostic pool of applications, the budget for individual projects is highly dependent on the disease area and methods proposed. The budget is expected to be not more than $3,000,000 direct costs/year. The project period may be up to three years. Date: Standard dates apply by 5:00 PM |
National Heart, Lung, and Blood Institute (NHLBI) |
Program Project applications relevant to NHLBI mission | This Funding Opportunity Announcement (FOA), issued by the National Heart, Lung, and Blood Institute (NHLBI) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also address implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective. Higher budgets may be requested for applications that include at least four projects, one of which has an Early Stage Investigator as Project Leader. | New (Type 1) and Renewal (Type 2) applications must limit their budget request to $1,515,000 in direct costs (excluding first-tier subcontract Facilities and Administrative [F&A] costs) or less in each year. If an ESI-led Project is included and the application contains a minimum of four Projects, New (Type 1) applications must limit their budget request to $1,765,000 in direct costs (excluding first-tier subcontract Facilities and Administrative [F&A] costs) in each year (with a minimum of $250,000 per year in direct costs for the ESI-led Project). The scope of the proposed program should determine the project period. The maximum program period is 5 years. Date: Standard dates apply by 5:00 PM |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
Alcohol-induced Effects on Tissue Injury and Repair | This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. This FOA also encourages the study of alcohol’s effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years. Date: Standard dates apply by 5:00 PM |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
Alcohol-induced Effects on Tissue Injury and Repair | This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Research Grant Award (R21) applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. This FOA also encourages the study of alcohol’s effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage. | The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is two years. Date: Standard dates apply by 5:00 PM |
National Institute of Mental Health (NIMH) |
Complex Brain Disorders, Neuronal Function | This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. The present announcement seeks R01 applications. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Mental Health (NIMH) |
Complex Brain Disorders, Neuronal Function | This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. The present announcement seeks R21 applications. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Aging (NIA), National Cancer Institute (NCI), National Center for Complementary and Integrative Health (NCCIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR) |
HIV and Aging | This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Aging (NIA), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR) |
HIV and Aging | This FOA encourages exploratory/developmental research applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD) |
Human Genome Research | This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. | Application budgets are limited to a combined total of no more than $275,000 in direct costs for the two year project. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), Fogarty International Center (FIC) |
Human Genome Research | This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. | Application budgets are limited to no more than $50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD) |
Human Genome Research | This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years, but given how quickly the field is evolving, it is expected that many projects will be no more than 3 years in duration. Longer project periods should be well justified. Additional consideration for longer projects may be given to new or early stage investigators. All applicants are strongly encouraged to discuss project length with Scientific/Research Staff prior to submission. Date: Standard dates apply, by 5:00 PM |
National Institute of Mental Health (NIMH), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA) |
Cell-Based Chemical Probes | This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NEI, NIAAA, NIDA, NIA and/or NIDCD and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 3 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
Secondary Analyses of Existing Alcohol Research Data | This Funding Opportunity Announcement (FOA) encourages the submission of investigator-initiated research grant applications to support the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems. Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
Secondary Analyses of Existing Alcohol Research Data | This Funding Opportunity Announcement (FOA) encourages the submission of investigator-initiated research grant applications to support the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems. Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest.
|
Application budgets are limited to $50,000 in direct costs per year. The total project period may not exceed two years. Date: Standard dates apply, by 5:00 PM |
Agency for Healthcare Research and Quality (AHRQ) |
Research Training Fellowship | The purpose of this individual postdoctoral research training fellowship is to enhance the research training of promising postdoctoral candidates who have the potential to become productive, independent investigators in health services research, with a research interest in areas and priorities relevant to the mission of AHRQ. | Award budgets are composed of stipends, tuition and fees, and institutional allowance, as described below. Individuals may receive up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants (e.g., T32) and an individual fellowship award. Date: Standard dates apply, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS) |
SBIR Phase IIB relevant to NINDS mission | This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIH’s SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period. | According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $1,500,000 for Phase II for specific topics. Durations up to 3 years for Phase II may be requested. Date: Standard dates apply, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS) |
Small Business Innovation Research (SBIR) relevant to NINDS mission | This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects requiring approval from a Federal regulatory agency or for those projects developing complex research tools. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NIH’s SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period. | According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $1,500,000 for Phase II for specific topics. Durations up to 3 years for Phase II may be requested. Date: Standard dates apply, by 5:00 PM |
National Human Genome Research Institute (NHGRI) |
Genomics | NHGRI invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years, but given how quickly the field is evolving, in order to ensure that the research is addressing the most current issues, many projects that are funded will be no more than 3 years in duration. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
Social Genomics approach to Chronic Wound Risk, Presence, Progression, and Healing | The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in addition to improving healing outcomes and quality of life. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
Social Genomics approach to Chronic Wound Risk, Presence, Progression, and Healing | The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in addition to improving healing outcomes and quality of life. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Cancer Institute (NCI) |
Follow-Up to Abnormal Screening Tests for Breast, Cervical, Colorectal, or Lung Cancers | This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD) |
HIV-Related Health Outcomes | The goal of this funding opportunity announcement (FOA) is to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD) |
HIV-Related Health Outcomes | The goal of this funding opportunity announcement (FOA) is to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR) |
Organ-Specific Cancer | This funding opportunity announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. For the purpose of this FOA, cancers derived from the same organ system (i.e., a group of organs that perform a common function) are considered related. Examples of such organ systems include gastrointestinal, endocrine and other biological systems. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers sustained and promoted by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant. | Approximately four to eight SPORE awards per year are anticipated. Applicants may request a maximum of $1,400,000 direct costs/year, which excludes third party indirect costs. Applications that include one or more qualified Early Detection, Prevention, or Population Science (qualified EPPS) project(s) may request up to an additional $120,000 direct costs/year to support this project(s), if appropriate. The maximum budget period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA) |
Osteoarthritis Initiative (OAI) | This Funding Opportunity Announcement (FOA) encourages applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. | The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA) |
Osteoarthritis Initiative (OAI) | This Funding Opportunity Announcement (FOA) encourages applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Aging (NIA) |
Technologies to Monitor the Daily Activities of Alzheimer's Disease Patients/At-Risk Individuals | This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R&D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD). | Budgets up to $350,000 total costs per year for Phase I and up to $2,000,000 total costs per year for Phase II may be requested. According to statutory guidelines, award periods normally may not exceed 1 year for Phase I and 2 years for Phase II. Date: Standard dates apply, by 5:00 PM |
National Institute on Aging (NIA) |
Technologies to Monitor the Daily Activities of Alzheimer's Disease Patients/At-Risk Individuals | This Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R&D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD). | Budgets up to $350,000 in total costs per year for Phase I and up to $2,000,000 in total costs per year for Phase II may be requested. According to statutory guidelines, award periods normally may not exceed 6 months for Phase I and 2 years for Phase II. Date: Standard dates apply, by 5:00 PM |
National Institute of Mental Health (NIMH) |
Psychiatric Disorders in areas of Unmet Medical Need | The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. PoC studies must evaluate the drug’s impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development | Application budgets are not limited but need to reflect the actual needs of the proposed project. For pharmacologic trials, the total project period may not exceed one year for FIH or Phase Ib and 3 years for PoC trials. Only applications that include both FIH and PoC trials may request 4 years. The duration of the device trial(s) must be appropriate for the proposed project, with a maximum of four years. NIMH encourages shorter project periods. Date: Standard dates apply, by 5:00 PM |
National Institute of Allergy and Infectious Diseases (NIAID) |
Primary Immunodeficiency Diseases | This Funding Opportunity Announcement (FOA) will support small grants on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research. The R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Investigators who have not received independent NIH funding or independent NIH funding in this field are encouraged to apply to this FOA. | A budget for direct costs of up to $50,000 per year may be requested (i.e., a maximum of $100,000 over two years). The project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Allergy and Infectious Diseases (NIAID) |
Primary Immunodeficiency Diseases | This Funding Opportunity Announcement (FOA) will support innovative exploratory/developmental investigations on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research. | Direct costs are limited to $275,000 over the two-year project period, with no more than $200,000 in direct costs allowed in any single year. The project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD) |
Ethical, Legal and Social Implications (ELSI) of Human Genome Research | This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years, but given how quickly the field is evolving, it is expected that many projects will be no more than 3 years in duration. Longer project periods should be well justified. Additional consideration for longer projects may be given to new or early stage investigators. All applicants are strongly encouraged to discuss project length with Scientific/Research Staff prior to submission. Date: Standard dates apply, by 5:00 PM |
National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), Fogarty International Center (FIC) |
Ethical, Legal and Social Implications (ELSI) of Human Genome Research | This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. | Application budgets are limited to no more than $50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date Standard dates apply, by 5:00 PM |
National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD) |
Ethical, Legal and Social Implications (ELSI) of Human Genome Research | This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. | Application budgets are limited to a combined total of no more than $275,000 in direct costs for the two year project, with no more than $200,000 in direct costs in a single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Pregnancy among Women with Disabilities | This funding opportunity announcement (FOA) issued by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) encourages research project grants (R01) investigating the incidence, course, and outcomes of pregnancy among women with disabilities. Areas of interest also include studies to inform preconceptional and antenatal counseling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimize outcomes for women with physical, intellectual and developmental, and/or sensory disabilities and their families. Applicants are encouraged to include women with disabilities and members of the community in the design and conduct of their research. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute of Mental Health (NIMH) |
Depressive Symptoms, Sudden Onset Acute Illness | The purpose of the funding opportunity announcement (FOA) is to encourage research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute of Mental Health (NIMH) |
Depressive Symptoms, Sudden Onset Acute Illness | The purpose of the funding opportunity announcement (FOA) is to encourage research on the etiology of depressive symptoms that occur in the context of a sudden onset acute illness. Although it is known that depressive symptoms may linger and affect functional recovery long after physical recovery from an acute insult, there is a gap in knowledge about the pathobiology that may underlie these incident depressive symptoms. A greater understanding of the etiological factors that contribute to and/or mitigate a trajectory of depressive symptoms may inform a personalized, holistic approach to managing recovery from acute illness. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of General Medical Sciences (NIGMS) |
Biomedical Research | The goal of the National Institute of General Medical Sciences (NIGMS)-sponsored Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant (T32) program is to develop a diverse pool of well-trained scientists available to address the Nation's biomedical research agenda. Specifically, this funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. | Application budgets are not limited, but need to reflect the actual needs of the proposed project. Grantees are expected to be familiar with and comply with applicable cost policies and the NRSA Guidelines (NIH Grants Policy Statement - Institutional Research Training Grants). Funds may be used only for those expenses that are directly related to and necessary for the research training and must be expended in conformance with OMB Cost Principles, the NIH Grants Policy Statement, and the NRSA regulations, policies, guidelines, and conditions set forth in this document. Awards may be for project periods up to five years in duration and are renewable. Date: Standard dates apply, by 5:00 PM |
National Cancer Institute (NCI) |
Commercial Development of Novel Cancer-Relevant Technologies | This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches. |
Date: Standard dates apply, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS) |
Neurological Emergencies | This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum requested project period cannot exceed 5 years but the actual funded project period is dependent on reaching specific milestones as described in this FOA. Date: Standard dates apply, by 5:00 PM |
National Center for Complementary and Integrative Health (NCCIH) |
Fundamental Science of Mind and Body Approaches | This funding opportunity announcement (FOA) encourages exploratory /developmental research grant applications (R21) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Center for Complementary and Integrative Health (NCCIH) |
Fundamental Science of Mind and Body Approaches | This Funding Opportunity Announcement (FOA) encourages research grant applications (R01) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Center for Complementary and Integrative Health (NCCIH) |
Fundamental Science of Mind and Body Approaches | This funding opportunity announcement (FOA) encourages exploratory /developmental research grant applications (R21) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Center for Complementary and Integrative Health (NCCIH) |
Fundamental Science of Mind and Body Approaches | This Funding Opportunity Announcement (FOA) encourages research grant applications (R01) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institutes of Health (NIH) |
Education and Health: New Frontiers (R21) | The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship. | The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. Date: Standard dates apply |
National Institutes of Health (NIH) |
Education and Health: New Frontiers (R03) | The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship. | The combined budget for direct costs for the two year project period may not exceed $100,000. No more than $50,000 in direct costs may be requested in any single year. Date: Standard dates apply |
National Institutes of Health (NIH) |
Education and Health: New Frontiers (R01) | The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship. | The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply |
National Institute on Aging (NIA) |
Aging | The NIA is committed to identifying effective treatments for diseases and conditions associated with aging and to ascertaining the associated health outcomes by supporting robust, well-planned and designed, and well-executed clinical trials and clinical research projects. | Total direct costs are limited to $450,000 over a three-year period, with no more than $225,000 in direct costs allowed in any single year. Date: Standard dates apply |
National Institutes of Health (NIH) (NIEHS) (NINR) |
Community Exposures to Environmental Contaminants | This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings. | Application budgets are not limited but need to reflect the actual needs of the proposed project. Date: Standard dates apply |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Accelerating Research on Intervertebral Disc (ARID) (R01) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage the submission of grant applications proposing studies on basic biology of the intervertebral disc. | Application budgets are not limited but need to reflect the actual needs of the proposed project. Date: Standard dates apply |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Accelerating Research on Intervertebral Disc (ARID) (R21) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage the submission of exploratory/developmental grant applications proposing studies on basic biology of the intervertebral disc. | The combined budget for direct costs for the two year project period may not exceed $275,000. Date: Standard dates apply |
National Institutes of Health (ORIP), (NIAD), (NIDCR), (NIEHS) |
Animal Stem Cells (R01) | This FOA encourages Research Project Grant (R01) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. | Application budgets are not limited but need to reflect the actual needs of the proposed project. Date: Standard dates apply |
National Institutes of Health (ORIP), (NIAD), (NIDCR), (NIEHS) |
Animal Stem Cells (R21) | This FOA encourages Exploratory/Developmental Research grant (R21) applications from institutions and organizations proposing research aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions. | The combined budget for direct costs for the two year project period may not exceed $275,000. Date: Standard dates apply |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Multidisciplinary Research in Vulvodynia (R21) | The purpose of this Funding Opportunity Announcement (FOA) is to indicate a continued interest in the topic area of vulvodynia or chronic vulvar pain of unknown etiology as an integral area of branch research. | The combined budget for direct costs for the two year project period may not exceed $275,000.No more than $200,000 may be requested in any single year. Date: Standard dates apply |
National Institute on Aging (NIA) |
Aging and Geriatric Research | The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution. | Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years. Date: Standard dates, by 5:00 PM |
National Institutes of Health (NIH) |
Mobile/wireless Health Technologies | Invites revision applications from investigators and institutions/organizations with active NIH-supported research project awards to support an expansion of the scope of approved and funded projects to incorporate recent advances in mobile/wireless tools to validate these tools for measurement and intervention delivery. | Application budgets are not limited but need to reflect the actual needs of the proposed project. Date: Standard dates apply |
National Institutes of Health (NIH), NIMH, NIAAA, NIDA |
Nervous System Disorders. | Encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders | Application budgets are not limited but need to reflect the actual needs of the proposed project. Date: Standard Due Dates Apply |
National Institutes of Health (NIH), NIMH, NIAAA, NIDA |
Drug Discovery For Nervous System Disorders (R21) | Encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. | Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. Date: Standard Due Dates Apply |
National Institutes of Health (NIH), NIDDK |
Intestinal Stem Cell | Encourages applications to conduct ancillary studies to the NIDDK Intestinal Stem Cell Consortium (ISCC). | Application budgets are not limited but need to reflect the actual needs of the proposed project. Date: Standard Due Dates Apply |
National Institutes of Health (NIH), NIDDK |
Brain | To promote progress in development of new technologies as well as in theory and data analysis, the BRAIN Initiative encourages collaborations between neurobiologists and researchers with expertise in statistics, physics, mathematics, engineering, and computer science, and NIH welcomes applications from investigators in these disciplines. | The direct costs are limited to $125,000 per year Date: Standard Due Dates Apply |
National Institute on Drug Abuse (NIDA) |
medications to prevent and treat opioid use disorders (OUD) and overdose | The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. This project is part of the NIH initiative to establish a public-private partnership to address the opioid crisis via more effective and safe ways to prevent and treat opioid use disorders and overdose. | NIDA intends to commit $10M in each fiscal year to a sufficient number of meritorious applications. NIDA intends to commit $10M in each fiscal year and to fund 3 to 4 grants per fiscal year. Application budgets are limited to $3 million direct costs per year and they need to reflect the actual needs of the proposed project. The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase. Date: Applications will be accepted on a rolling basis, beginning on January 25, 2018 |
National Institute on Drug Abuse (NIDA) |
HIV prevention and treatment for PWID | This FOA supports developing and testing implementation approaches that scale-up evidence based interventions in low to middle income countries among PWID where they form an important component of the national HIV epidemic, including countries where PWID are a relatively emergent population for HIV cases. Projects need to align with national HIV/AIDS plans and provide models for large scale implementation, including QA/QC systems. Collaboration with local or regional PEPFAR and Global Fund programs is encouraged. Recently introduced syringe services and drug treatment settings should be leveraged as well as new health financing systems, criminal justice reforms or other local innovations that can be used to expand HIV prevention and treatment for PWID. Collaboration with NIH initiatives such as IeDEA (NIH’s cohort of cohorts co-funded by NIDA) and existing NIDA-funded projects is encouraged. | NIDA intends to commit $3,000,000 in FY 2018 to fund 3-5 awards, and NIDA intends to commit $1,500,000 in FY 2019 to fund 1-2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: April 13, 2018 and November 15, 2018, by 5:00 PM |
National Institute on Drug Abuse (NIDA) |
HIV-1 pathogenesis in individuals with substance use disorders (SUDs) | The goal of this Funding Opportunity Announcement [FOA] is to support research that will define and validate a set(s) of molecular biomarkers and/or bio-signatures indicating the degree of loss of functional reserve, or of resilience of the host defense mechanisms, at different phases of HIV-1 pathogenesis in individuals with substance use disorders (SUDs). | NIDA intends to commit $3,000,000.00 in FY 2018 to fund 6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: April 17, 2018 , by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH) |
recording and/or stimulating devices to treat nervous system disorders and better understand the human brain | The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational and clinical studies for recording and/or stimulating devices to treat nervous system disorders and better understand the human brain. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and a subsequent small clinical trial (e.g., Early Feasibility Study). The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. Individuals, institutions or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this FOA or RFA-NS-18-023. | The NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The duration of the UG3 phase cannot exceed 4 years and the total duration of the UG3/UH3 phases combined may not exceed 5 years. Date: February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH) |
recording and/or stimulating devices to treat nervous system disorders and better understand the human brain | The purpose of this Funding Opportunity Announcement (FOA) is to encourage small business concerns (SBCs) to pursue translational non-clinical studies and clinical studies for recording and/or stimulating devices to treat nervous system disorders and thereby better understand the human brain. The program will utilize a cooperative agreement mechanism to support the non-clinical studies necessary for the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or to obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and the subsequent small clinical trial (e.g., Early Feasibility Study). Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. | NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Applications should rarely exceed $1,000,000 in total cost per year during the SBIR Phase I and $1,500,000 in total costs per year during the SBIR Phase II. Durations up to 2 years for SBIR Phase I and up to 3 years for SBIR Phase II may be requested. Date: February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH) |
recording and/or stimulating devices to treat nervous system disorders and better understand the human brain | The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study). Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical trial to answer key questions about the function or final design of a device .Individuals, institutions or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to RFA-NS-18-021 or this FOA. | The NIH anticipates providing $10M per year to fund an estimated 5 to 7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $2M per year. The total duration may not exceed 5 years. Date: February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS) |
pathobiology, pathophysiology, and neuropathology of neurological disorders | This FOA supports hypothesis-driven mechanistic clinical trial studies in basic and/or translational discovery research in healthy human subjects and in the pathobiology, pathophysiology, and neuropathology of neurological disorders. The goal is to address basic questions and to interrogate concepts in biology, behavior, and pathophysiology that will provide insight into understanding neurological disorders. Such studies may seek to understand a biological or behavioral process, or the mechanism of action of an intervention. NINDS supports biomarker studies that may provide information about physiological function, target engagement of novel therapeutics, and/or mechanisms of therapeutic responses. The submitted studies are defined as clinical trials (NOT-OD-15-015) but do not seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions. preventive, therapeutic, and services interventions. Such designs should be submitted to an NINDS clinical trial-specific funding announcement (listed on the NINDS website at https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research). Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. | Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS) |
early career investigators from underrepresented groups in neuroscience research | The NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity is designed to enhance the participation of highly trained early career investigators from underrepresented groupsin neuroscience research. This opportunity provides postdoctoral fellows from underrepresented groupswith strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA PAR-18-468). | Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years. Date: Standard dates apply, by 5:00 PM |
National Cancer Institute (NCI) |
Curriculum or Methods Development | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients. | The maximum budget is $150,000 direct costs/year. The budget request for a given application needs to be adequately justified and reflect the actual needs of the proposed project. Yearly fluctuations in the project workload should be reflected in the requested budget. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Cancer Institute (NCI) |
Courses for Skills Development | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients. | The maximum budget is $300,000 direct costs/year. The budget request for a given application needs to be adequately justified and reflect the actual needs of the proposed project. Yearly fluctuations in the project workload should be reflected in the requested budget. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Cancer Institute (NCI) |
Research Experiences | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients. | The maximum budget is $300,000 direct costs/year. The budget request for a given application needs to be adequately justified and reflect the actual needs of the proposed project. Yearly fluctuations in the project workload should be reflected in the requested budget. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Mental Health (NIMH) |
reducing the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system | This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system. Opportunities for detection and prevention start at early points of contact (e.g., police interaction, the intake interview) and continue through many juvenile justice settings (e.g., pre-trial detention, juvenile or family court activities, court disposition, placement and on-going care in either residential or multiple community settings.) This FOA invites intervention strategies that are designed to be delivered in typical service settings using typically available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm in this population. This FOA is published in parallel to a companion R34 FOA (PAR-18-228) supporting pilot studies in preparation for the larger-scale studies described here. | NIMH intends to commit $1.3 million dollars for this and the companion R34 announcement (PAR-18-228) to fund 4 awards in this initiative. Application budgets are limited to $500,000 direct costs per budget year and should reflect the actual needs of the proposed project. The total project period for applications submitted in response to this FOA may not exceed five years. Date: Standard dates apply, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS) |
pathobiology, pathophysiology, and neuropathology of neurological disorders | This FOA supports hypothesis-driven mechanistic clinical trial studies in basic and/or translational discovery research in healthy human subjects and in the pathobiology, pathophysiology, and neuropathology of neurological disorders. The goal is to address basic questions and to interrogate concepts in biology, behavior, and pathophysiology that will provide insight into understanding neurological disorders. Such studies may seek to understand a biological or behavioral process, or the mechanism of action of an intervention. NINDS supports biomarker studies that may provide information about physiological function, target engagement of novel therapeutics, and/or mechanisms of therapeutic responses. The submitted studies are defined as clinical trials (NOT-OD-15-015) but do not seek to answer specific questions about safety, tolerability, clinical efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions. preventive, therapeutic, and services interventions. Such designs should be submitted to an NINDS clinical trial-specific funding announcement (listed on the NINDS website at https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research). | Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years. NINDS anticipates that most Diversity Faculty K01 awards will be 5 year awards and applicants should propose a research plan that reflects the total project period (up to 5 years); however, if the year 3 administrative review determines that an investigator is not applying for appropriate research grants or making sufficient progress towards preliminary data for such a submission, the award may not be extended. Date: Standard dates apply, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS) |
early career investigators from underrepresented groups in neuroscience research | The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA PAR-18-486). | Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years. Initial budget period to be awarded is 3 years and a continuation for years 4 and 5 are contingent on administrative review by NINDS staff. NINDS anticipates that most Diversity Faculty K01 awards will be 5 year awards and applicants should propose a research plan that reflects the total project period (up to 5 years); however, if the year 3 administrative review determines that an investigator is not applying for appropriate research grants or making sufficient progress towards preliminary data for such a submission, the award may not be extended. Date: Standard dates apply, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS) |
fundamental questions in basic neuroscience | The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related. | NINDS intends to fund up to 12 awards, corresponding to a total of $5.0 million for fiscal year 2019. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
neonatal and pediatric resuscitation | The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Applications can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies, prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
neonatal and pediatric resuscitation | The purpose of this funding opportunity announcement (FOA) is to stimulate research on a wide range of topics related to neonatal and pediatric resuscitation. Possible topics may include, but are not limited to: fetal-neonatal transitional cardiovascular and pulmonary physiology, optimizing steps of resuscitation, management of third stage of labor and its effect on the fetus, resuscitation of children with malformations, effect of resuscitation on long-term outcomes and post-resuscitation practices. Proposals can include epidemiological studies, studies utilizing fetal-neonatal animal models, computer or other information-technology-based simulations or study designs, clinical observational studies, analyses of pre-existing national or regional datasets, opportunistic studies prospective randomized controlled trials, or any combinations thereof. It is anticipated that the results from well-conducted studies will enable translation of knowledge into evidence-based resuscitation practices ensuring a optimal short- and long-term outcomes for all newborn infants and children. | Application budgets are limited to $50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Cancer Institute (NCI) |
systematic screening and treatment of depression in cancer patients | The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the usability and potential effectiveness of the IT-specific components of these new delivery models. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in a single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Cancer Institute (NCI) |
systematic screening and treatment of depression in cancer patients | The purpose of this Funding Opportunity Announcement (FOA)is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
EOLPC health literacy | This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
EOLPC health literacy | This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Eye Institute (NEI) |
visual system | The purpose of this FOA is to encourage applications that seek to conduct studies of the visual system. Applications that will be supported may be either: Those that involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or those that are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Aging (NIA), National Center for Complementary and Integrative Health (NCCIH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI) |
palliative care in geriatric populations | This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Aging (NIA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI) |
palliative care in geriatric populations | This Funding Opportunity Announcement (FOA) encourages exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings. This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and limited interventional studies where feasible for this R21 mechanism. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Dental and Craniofacial Research (NIDCR) |
dental, oral and craniofacial health | The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical specialty training at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-16-156). | Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 7 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Biomedical Imaging and Bioengineering (NIBIB) |
exploratory/developmental research projects of interest to the NIBIB | This FOA will support exploratory/developmental research projects of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. | Application budgets may not exceed $275,000 direct costs over a maximum two-year funding period. No more than $200,000 in direct costs may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Cancer Institute (NCI), National Center for Complementary and Integrative Health (NCCIH) |
synthetic biology for human health | This Funding Opportunity Announcement (FOA) invites applications to conduct research to advance the understanding and application of synthetic biology for human health. It will support 1) the development of innovative tools and technologies in synthetic biology and 2) their application in biomedical research and human health. An integrative research plan based on collaborations of synthetic biologists with computational scientists, cell biologists, engineers, and/or physician scientists is strongly recommended. Early Stage Investigators in Synthetic Biology are especially encouraged to apply. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum award project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Eye Institute (NEI), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH) |
novel neurotechnologies commercialization | The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience research. | According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. Durations up to two years for Phase I and up to three years for Phase II may be requested. Date: Standard dates apply, by 5:00 PM |
National Eye Institute (NEI), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH) |
novel neurotechnologies commercialization | The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice. | According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. Durations up to two years for Phase I and up to three years for Phase II may be requested. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute on Aging (NIA) |
biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment (MCI), or disease- or age-related cognitive decline | The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute on Aging (NIA) |
biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment (MCI), or disease- or age-related cognitive decline | The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: |
National Institute of Nursing Research (NINR), National Institute on Aging (NIA) |
self-management for health in chronic conditions | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
Community Engaged Research (CEnR) methodologies | This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
Community Engaged Research (CEnR) methodologies | This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute on Aging (NIA) |
self-management for health in chronic conditions | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
symptom and genomic nursing science | This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived. | Applicants may request up to $300,000 in direct costs for the entire project period of up to 3 years. The scope of the proposed project should determine the project period. The maximum project period is 3 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness | The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. | Applicants may request up to $300,000 in direct for the entire project period of up to 3 years. The scope of the proposed project should determine the project period. The maximum project period is 3 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute on Aging (NIA) |
biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment (MCI), or disease- or age-related cognitive decline | The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers. | Applicants may request up to $300,000 in direct costs for the entire project period of up to 3 years. The scope of the proposed project should determine the project period. The maximum project period is 3 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR), National Institute on Aging (NIA) |
self-management for health in chronic conditions | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions. | Applicants may request up to $300,000 in direct costs for the entire project period of up to 3 years. The scope of the proposed project should determine the project period. The maximum project period is 3 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Hidradenitis Suppurativa | This Funding Opportunity Announcement (FOA) will support high risk and high reward basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients’ condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period. The maximum project period is 2 years. Date: Standard dates apply by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Hidradenitis Suppurativa | This Funding Opportunity Announcement (FOA) will support basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients’ condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. | Application budgets must reflect the actual needs of the proposed project and is limited to direct costs of no more than $500,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of Dietary Supplements (ODS) |
obesity in adults and/or children | This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program. | Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. The maximum project period is two years. Date: Standard dates apply by 5:00 PM |
Office of Behavioral and Social Sciences Research (OBSSR), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH) |
patient adherence to treatment and prevention regimens to promote health outcomes | This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes and Centers. This FOA calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s). | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period.The maximum project period for this FOA is 5 years. |
Office of Behavioral and Social Sciences Research (OBSSR), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD) |
patient adherence to treatment and prevention regimens to promote health outcomes | This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes and Centers. This FOA calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider and/or healthcare system, and community levels. Attention to scientific rigor in all applications is paramount, with emphasis on appropriate sample sizes, valid outcome measures, and testing intervention mechanisms of action. The specific research interests of participating NIH Institutes and Centers are detailed within. This FOA accepts applications that either propose or do not propose a clinical trial(s). | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: Standard dates apply by 5:00 PM |
National Institute of Allergy and Infectious Diseases (NIAID) |
National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) | The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply by 5:00 PM |
National Institute of Allergy and Infectious Diseases (NIAID) |
National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) | The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), Division of Program Coordination, Planning and Strategic Initiatives: Sexual & Gender Minority Research Office (SGMRO), Office of AIDS Research (OAR), Office of Research on Women’s Health (ORWH) |
health of transgender and gender nonconforming people | This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex. | Application budgets are not to exceed $275,000 in direct costs for the entire duration of the grant. No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: Standard dates apply by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), Division of Program Coordination, Planning and Strategic Initiatives: Sexual & Gender Minority Research Office (SGMRO), Office of AIDS Research (OAR), Office of Research on Women’s Health (ORWH) |
health of transgender and gender nonconforming people | This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply by 5:00 PM |
Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI) |
genetics of childhood cancers and/or structural birth defects | The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed. | The combined budget for direct costs for the two year project period may not exceed $200,000. A project duration of up to two years may be requested. Date: Standard dates apply by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS) |
basic science-clinical collaborations | The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. Applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects. | Application budgets for up to $75,000 direct costs per year are allowed but should reflect the actual needs of the proposed project. The maximum project period is two years. Date: Standard dates apply by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA) |
nonmalignant hematology research | This Funding Opportunity Announcement (FOA) is calling for R01 grant applications in nonmalignant hematology research. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build and promote research activities in nonmalignant hematology. Innovative research project applications that will steer the field in new directions are invited. Each project will propose proof of principle research that is tightly focused into one specific aim and is directed at validating novel concepts and approaches that promise to open up new pathways for discovery. Research applications submitted under this FOA should be more limited in scope (a single central aim) and duration (1-3 years) than typical R01 grant applications. | Each participating Institute intends to fund an estimate of 2-5 awards beyond its regular/standard R01 funding policies, corresponding to a total of approximately $3,000,000 additional funds for fiscal year 2019 and beyond. Application budgets should reflect the actual needs of the proposed project and should be limited to no more than $200,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is three years. Date: Standard dates apply by 5:00 PM |
National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Nursing Research (NINR) |
role of the microbiome in health and disease during aging | The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period may not exceed 5 years. Date: Standard dates apply by 5:00 PM |
National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Nursing Research (NINR) |
role of the microbiome in health and disease during aging | The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as relate to health and disease. This FOA will accept basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: Standard dates apply by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
diabetes and selected endocrine and metabolic diseases | This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing’s diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data. | Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. Application budgets need to reflect the actual needs of the proposed project. The total project period may not exceed 2 years. Date: Standard dates apply by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
urologic disorders research | This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders. | The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: Standard dates apply by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
kidney disease research | This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases. | Direct costs are limited to $275,000 over the two-year period. No more than $200,000 in direct costs may be requested in any single year. The total project period may not exceed 2 years. Date: Standard dates apply by 5:00 PM |
Agency for Healthcare Research and Quality (AHRQ) |
ambulatory care settings and long term care facilities | AHRQ's Center for Quality Improvement and Patient Safety (CQuIPS) works to ensure patient safety in multiple settings with recent efforts to increase the development of processes including measures, metrics, tools and practices to increase patient safety in the ambulatory care setting and long term care facilities. This Funding Opportunity Announcement (FOA) will fund large research demonstration and implementation projects that pertain to ambulatory care settings and long term care facilities with a focus on implementing evidence-based processes to improve patient safety, especially those involving transitions in care. AHRQ is interested in studies in these two settings that develop, utilize, and evaluate strategies to implement existing measures, metrics, tools or practices that have already been validated and have been shown to be efficacious in improving patient safety sites. | Total annual costs (combined direct and indirect) for an individual grant awarded under this FOA will not exceed $450,000 in any given year or $1.35 million for the entire project period. Funds may be used only for those expenses that are directly related and necessary to the project and must be expended in compliance with applicable OMB Uniform Administrative Requirements, Cost Principles, and Audit Requirements, Cost Principles, and Audit Requirements for HHS Awards (45 CFR Part 75) and the HHS Grants Policy Statement. The project period may not exceed 3 years. Date: Standard dates apply by 5:00 PM |
National Institute on Aging (NIA) |
research participant recruitment and retention | This funding opportunity announcement encourages collaborative teams to target gaps in methods and outcomes regarding research participant recruitment and retention. The team approach encouraged by this initiative will be used to generate a research resource to advance processes for high yield recruitment, formulate breakthrough ideas, concepts and approaches to research participant recruitment and retention, strengthen outreach and community engagement practices, and devise improved communication strategies. Teams will demonstrate the success of these improvements by engaging a large diverse population. The primary outcome will be the development of a population of diverse community members ready to engage in NIA funded clinical research studies. | NIH intends to fund an estimate of 1-3 awards, corresponding to a total of $3 million, for fiscal year 2019. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 3 years. Date: Standard dates apply by 5:00 PM |
National Institute on Drug Abuse (NIDA) |
collaborative research on drug abuse and addiction | This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that: 1. Take advantage of unusual opportunities that exist outside the United States to access talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery 2. Describe how the research will significantly advance U.S. health sciences 3. Demonstrate specific relevance to the NIDA mission and objectives. To determine whether your research plan is relevant to the NIDA mission and objectives, review the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). Where feasible, applications should address NIDA’s international scientific priority areas (https://www.drugabuse.gov/international/research-priorities) 4. Include an investigator from a U.S. institution and a non-U.S. citizen partner living and working in another country. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Drug Abuse (NIDA) , National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
larger-scale services research effectiveness trials | This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities. | Direct costs are limited to $450,000 over the 3-year project period, with no more than $225,000 in direct costs allowed in any single year. The total project period for an application submitted may not exceed three years. Date: Standard dates apply, by 5:00 PM |
National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use | This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, prevent suicide attempts (nonfatal and fatal), and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems. | Applicants may request direct costs of up to $450,000 for three years. Although variations from year to year are permissible, in no case may any year be more than $225,000 in direct costs, and total direct costs for the entire project period may not exceed $450,000. The maximum project period is 3 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Nursing Research (NINR) |
maternal nutrition and pre-pregnancy obesity | This Funding Opportunity Announcement (FOA) encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intrauterine environment, and subsequently fetal development and the health of the newborn. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years. Date: Standard dates apply, by 5:00 PM |
National Heart, Lung, and Blood Institute (NHLBI) |
functional microbiome research | The purpose of this funding opportunity announcement (FOA) is to support functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
development of wearable device to monitor blood alcohol levels in real time | The purpose of this funding opportunity announcement is to encourage Small Business Technology Transfer (STTR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of highest priority. | According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. According to statutory guidelines, award periods normally may not exceed 1 year for Phase I and 2 years for Phase II. Date: Standard dates apply, by 5:00 PM |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
development of wearable device to monitor blood alcohol levels in real time | The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of highest priority. | According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. According to statutory guidelines, award periods normally may not exceed 6 months for Phase I and 2 years for Phase II. Date: Standard dates apply, by 5:00 PM |
National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Cancer Institute (NCI) |
diseases and conditions in the oral cavity and oropharynx | The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period request may not exceed 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute of Dental and Craniofacial Research (NIDCR) |
diseases and conditions in the oral cavity and oropharynx | The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. | Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units | This funding opportunity announcement (FOA) encourages a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. | Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: Standard dates apply, by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
patient safety in the context of both routine as well as intensive newborn care | This funding opportunity announcement (FOA) encourages a wide range of collaborative research projects related to patient safety in the context of both routine as well as intensive newborn care. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors in the context neonatal care. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants with utmost safety and effectiveness. | Application budgets are limited to $50,000 in direct costs per year. The maximum project period is 2 years. Date: Standard dates apply, by 5:00 PM |
Agency for Healthcare Research and Quality (AHRQ) |
research on disseminating evidence into practice through shared, interoperable clinical decision support (CDS) resources | This Funding Opportunity Announcement (FOA) invites U18 cooperative agreement applications for innovative research on disseminating evidence into practice through shared, interoperable clinical decision support (CDS) resources. | The total costs (direct and indirect) for a project awarded under this FOA will not exceed $500,000 in any given year or $1 million for the entire project period. The project period may not exceed 2 years. Date: Standard dates apply, by 5:00 PM |
Agency for Healthcare Research and Quality (AHRQ) |
discrete, specified health services research project | The Research Demonstration and Dissemination Grant (R18) is an award made by AHRQ to an institution/organization to support a discrete, specified health services research project. The project will be performed by the named investigator and study team. The R18 research plan proposed by the applicant institution/organization must be related to the mission and priority research interests of AHRQ. | The total costs (direct and indirect costs) awarded to a grant under this FOA will not exceed $400,000 in any given year for the entire project period. An application with a budget that exceeds $400,000 total costs in any given year will not be reviewed. The maximum project period for an application submitted under this FOA is 5 years. Date: Standard dates apply, by 5:00 PM |
Agency for Healthcare Research and Quality (AHRQ) |
health services research projects | This FOA encourages Small Research Grant (R03) applications, and expresses AHRQ priority areas of interest for ongoing small research projects. The R03 grant mechanism supports different types of health services research projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. | Application budgets are limited to $100,000 total costs (including direct and indirect costs) for the entire project period, regardless of the length of the proposed project period. An application with a budget that exceeds $100,000 total costs for the entire project period will not be reviewed. The maximum project period for an application submitted under this FOA is 2 years. Date: Standard dates apply, by 5:00 PM |
Agency for Healthcare Research and Quality (AHRQ) |
health services research projects | The Research Project Grant (R01) is an award made by AHRQ to an institution/organization to support a discrete, specified health services research project. The project will be performed by the named investigator and study team. The R01 research plan proposed by the applicant institution/organization must be related to the mission and priority research interests of AHRQ | The total costs (direct and indirect costs) awarded to a grant under this FOA will not exceed $400,000 in any given year for the entire project period. An application with a budget that exceeds $400,000 total costs in any given year will not be reviewed. The maximum project period for an application submitted under this FOA is 5 years. Date: Standard dates apply, by 5:00 PM |
National Institute on Deafness and Other Communication Disorders (NIDCD) |
Audiologists, Mentored Research | The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research training experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Award budgets are composed of salary and other program-related expenses, as described below. The total project period may not exceed 3 years. Date: October 18, 2016; February 17, 2017; June 19, 2017; October 17, 2017; February 15, 2018; June 19, 2018; October 19, 2018; February 15, 2019; and June 18, 2019, by 5:00 PM |
National Cancer Institute (NCI) |
Cancer and Neuroscience Research Collaboration | This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: October 26, 2016; February 22, 2017; June 27, 2017; October 26, 2017; February 22, 2018; June 27, 2018; October 25, 2018; February 22, 2019; June 27, 2019, by 5:00 PM |
National Cancer Institute (NCI) |
Cancer and Neuroscience Research Collaboration | This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Date: October 26, 2016; February 22, 2017; June 27, 2017; October 26, 2017; February 22, 2018; June 27, 2018; October 27, 2018; February 22, 2019; June 27, 2019, by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Human Development and Pathologies | This Funding Opportunity Announcement (FOA) encourages grant applications aimed at the collection, identification, staging, and distribution of conceptual tissues for use in studies to understand the underlying developmental biology of normal and abnormal human development as well as human pathologies. The objective of this FOA is to provide support for established resources that serve the research community. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: October 27, 2016, January 30, 2017, May 30, 2017, September 27, 2017, January 30, 2018, May 30, 2018, September 26, 2018, January 30, 2019, May 30, 2019, by 5:00 PM |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), Office of Behavioral and Social Sciences Research (OBSSR) |
Behavioral Factors Related to Obesity Prevention and Treatment | The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications to support the addition of measures of psychological and/or behavioral constructs or weight-related variables (e.g.; BMI, body composition) to existing or new research studies in humans with the goal of elucidating behavioral or psychological phenotypes that explain individual variability in weight trajectory or response to obesity prevention or treatment interventions. The intent is to support the addition of new measurement in domains other than those covered in the parent grant as a means of elucidating the behavioral and psychological factors that may explain individual differences in weight status. For the purposes of this FOA, behavioral factors related to energy intake include overt actions/behavior (e.g.; objective observation of eating event including measures such as quantity, selection/quality, and speed of intake) and underlying psychological processes related to self-regulation of intake such as cognitive control, affective response, learning, and motivation. The rationale is that an improved understanding of the individual characteristics and processes that explain energy intake patterns can lead to better matching of individuals to prevention or treatment approaches and identify novel targets for more efficacious individual and population level approaches to weight management. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: October 28, 2016; February 28, 2017; June 28, 2017; February 28, 2018; June 28, 2018; February 28, 2019, by 5:00 PM |
National Institute on Deafness and Other Communication Disorders (NIDCD) |
Human Communication Disorders | The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Budgets for new applications are limited to $1,500,000/year direct cost (DC). Renewal (type 2) grant applications may request budgets (DC) that are no greater than 10% above the budget of the last year of the existing grant or $2,000,000 whichever is less. Annual budget increases should not exceed more than NIH allowances at the time of submission of the application. Salary levels in all years are limited to the NIH maximum rate. Revision applications requesting an additional research component to an existing P50 are allowed, but may not exceed the terms of the parent award or the budgetary caps as described above. The maximum project period is 5 years. Date: October 3, 2016; February 1, 2017; June 1, 2017; October 2, 2017; February 1, 2018; June 1, 2018; October 1, 2018; February 1, 2019; June 3, 2019, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women’s Health (ORWH) |
Brain Initiative | This RFA will support integrated, interdisciplinary research teams from prior BRAIN technology and/or integrated approaches teams, and/or new projects from the research community that focus on examining circuit functions related to behavior, using advanced and innovative technologies. The goal will be to support programs with a team science approach that can realize meaningful outcomes within 5-plus years. Awards will be made for 5 years, with a possibility of one renewal. Projects will incorporate overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Applications should incorporate theory-/model-driven experimental design and should offer predictive models as deliverables. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Applications are expected to employ approaches guided by specified theoretical constructs, and are encouraged to employ quantitative, mechanistic models where appropriate. Applications will be required to manage their data and analysis methods in a prototype framework that will be developed and used in the proposed U19 project and exchanged with other BRAIN U19 awardees for further refinement and development. Model systems, including the possibility of multiple species ranging from invertebrates to humans, can be employed and should be appropriately justified. Programs should employ multi-component teams of research expertise – including neurobiologists, statisticians, physicists, mathematicians, engineers, computer scientists, and data scientists, as appropriate - that seek to cross boundaries of interdisciplinary collaboration. | maximum project period is 5 years. budgets are not limited but need to reflect the actual needs of the proposed project. Date: October 30, 2018, October 30, 2019 and October 30, 2020, by 5:00 PM |
National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women’s Health (ORWH) |
Brain Initiative | This RFA will support integrated, interdisciplinary research teams from prior BRAIN technology and/or integrated approaches teams, and/or new projects from the research community that focus on examining circuit functions related to behavior, using advanced and innovative technologies. The goal will be to support programs with a team science approach that can realize meaningful outcomes within 5-plus years. Awards will be made for 5 years, with a possibility of one renewal. Projects will incorporate overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Applications should incorporate theory-/model-driven experimental design and should offer predictive models as deliverables. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Applications are expected to employ approaches guided by specified theoretical constructs, and are encouraged to employ quantitative, mechanistic models where appropriate. Applications will be required to manage their data and analysis methods in a prototype framework that will be developed and used in the proposed U19 project and exchanged with other BRAIN U19 awardees for further refinement and development. Model systems, including the possibility of multiple species ranging from invertebrates to humans, can be employed and should be appropriately justified. Programs should employ multi-component teams of research expertise – including neurobiologists, statisticians, physicists, mathematicians, engineers, computer scientists, and data scientists, as appropriate - that seek to cross boundaries of interdisciplinary collaboration. | maximum project period is 5 years. budgets are not limited but need to reflect the actual needs of the proposed project. Date: October 30, 2018, October 30, 2019 and October 30, 2020, by 5:00 PM |
National Human Genome Research Institute (NHGRI) |
Genomic Innovator | This program aims to support researchers to do highly innovative work on important problems in genomics. The PD/PIs should be creative investigators, early in their careers, who are part of consortia, large research groups, or other team-science efforts. They should have New Investigator status and have shown the potential to make important contributions to the field of genomics. PD/PIs will have flexibility to take their research in novel directions as scientific opportunities arise during this award. | project period is five years. may request up to $300,000 direct costs per year Date: October 30, 2018; October 30, 2019; October 30, 2020, by 5:00 PM |
National Center for Advancing Translational Sciences (NCATS) |
Pre-applicationfor the NIH Industry Program | This Funding Opportunity Announcement (FOA) invites pre-applications for projects that test new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases in adult and pediatric populations. This innovative program allows investigators to propose new therapeutic uses for Assets from pharmaceutical company partners. Strong applications will include scientific evidence that modulation of an Asset’s target will have a positive impact on the disease/condition. | Not Applicable. Date: October 31, 2018, April 29, 2019, October 31, 2019, April 29, 2020, October 31, 2020, April 29, 2021 , by 5:00 PM |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). |
Pediatric research program | The purpose of this Funding Opportunity Announcement (FOA) is to establish one or two centers that can rapidly generate high quality whole genome sequence and variant data from a large number of human specimens representing two types of pediatric conditions - childhood cancers and structural birth defects. All sequence data generated under this FOA will be re-processed and harmonized by the Gabriella Miller Kids First Pediatric Data Resource Center (Kids First DRC), which is also charged with building a public-facing, web-based portal that will allow researchers to search, access, aggregate, analyze, and share annotated genomic sequence, variant, and phenotypic datasets. Together these resources will promote comprehensive and cross-cutting research and collaboration within the pediatric research community. | award period for this FOA is 3 years (FY2019 - FY2021). budgets for each year should not exceed $8M in total costs. Date: October 31, 2018, by 5:00 PM |
National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD) |
Adverse Drug Reactions | This Funding Opportunity Announcement is to support research grants that will advance the state of knowledge of serious adverse drug reactions. Applications across the spectrum of research are encouraged. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years. Date: October 4, 2016; February 1, 2017; June 1, 2017; October 2, 2017; February 1, 2018; June 1, 2018; October 1, 2018; February 1, 2019; June 3, 2019, by 5:00 PM |
National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD) |
Adverse Drug Reactions | This Funding Opportunity Announcement is to support research grants that will advance the state of knowledge of serious adverse drug reactions. Applications across the spectrum of research are encouraged. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years. Date: October 4, 2016; February 1, 2017; June 1, 2017; October 2, 2017; February 1, 2018; June 1, 2018; October 1, 2018; February 1, 2019; June 3, 2019, by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Rheumatic Disease | The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK X02 and R61/R33 FOAs are not intended to support clinical trials. | Not Applicable. No awards will be made under this announcement. Awards will be made through the companion FOA, RFA-AR-19-012. Date: October 4, 2018; July 3, 2019 by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Musculoskeletal Diseases | The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK X02 and R61/R33 FOAs are not intended to support clinical trials. | Not Applicable. No awards will be made under this announcement. Awards will be made through the companion FOA, RFA-AR-19-013. Date: October 4, 2018; July 3, 2019, by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
skin and rheumatic diseases | The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK X02 and R61/R33 FOAs are not intended to support clinical trials. The RISK program will support the two main scientific areas of NIAMS mission, 1) musculoskeletal diseases and 2) the skin and rheumatic diseases. This X02 pre-application and the companion R61/R33 (RFA- AR-19-012) encourage applications related to skin and rheumatic diseases. |
Not Applicable. No awards will be made under this announcement. Awards will be made through the companion FOA, RFA-AR-19-012. Date: October 4, 2018; July 3, 2019, by 5:00 PM |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
Musculoskeletal Diseases | The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK X02 and R61/R33 FOAs are not intended to support clinical trials. The RISK program will support the two main scientific areas of NIAMS mission, 1) musculoskeletal diseases and 2) the skin and rheumatic diseases. This X02 pre-application and the companion R61/R33 (RFA-AR-19-013) encourage applications related to musculoskeletal diseases. | Not Applicable. No awards will be made under this announcement. Awards will be made through the companion FOA, RFA-AR-19-013. Date: October 4, 2018; July 3, 2019, by 5:00 PM |
National Cancer Institute (NCI) |
Caregivers of Adult Cancer Patients | This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Date: October 7, 2016; April 11, 2017; October 10, 2017; April 11, 2018; October 10, 2018, April 11, 2019, by 5:00 PM |
National Cancer Institute (NCI) |
Caregivers of Adult Cancer Patients | This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: October 7, 2016; April 11, 2017; October 10, 2017; April 11, 2018; October 10, 2018, April 11, 2019, by 5:00 PM local time |
National Cancer Institute (NCI) |
Population-Level Strategies Targetting Cancer-Related Behaviors | The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years. Date: October 7, 2016; April 11, 2017; October 10, 2017; April 11, 2018; October 10, 2018; April 11, 2019, by 5:00 PM |
National Institute on Deafness and Other Communication Disorders (NIDCD) |
Hearing, Balance, Smell, Taste, Voice, Speech and Language Sciences | The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences. | The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIDCD anticipates funding 3 to 5 awards, corresponding to a projected total of $600,000 per year. Award budgets are composed of salary and other program-related expenses, as described below. Generally, the research experience shall span a contiguous period of six months to two years. Date: October 7, 2016; February 8, 2017; June 8, 2017; October 6, 2017; February 8, 2018; June 8, 2018; October 9, 2018; February 8, 2019; and June 6, 2019, by 5:00 PM |
National Institute of Mental Health (NIMH), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), Office of Research on Women’s Health (ORWH) |
Brain Initiative | The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative funding opportunity announcement is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell and circuit specific tools will require extensive focused research designed to remove barriers to delivery of gene therapies. In addition to identification and removal of barriers, the need to specifically target dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cutting-edge tools have been developed for use in model organisms, primarily rodents, fish and flies. These cutting-edge tools, such as viral delivery of genetic constructs, are increasingly adaptable to larger mammalian brains and more importantly are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains or those that are more directly relevant to the human brain is the focus of this initiative. The initiative will support initial proof of principle studies aimed at demonstrating the feasibility of this approach in humans and other mammalian species (non-human primate [NHP]/sheep/pigs). | The duration of the UG3 phase cannot exceed 3 years and the total duration of the UG3/UH3 phases combined may not exceed 5 years. budgets are not limited but need to reflect the actual needs of the proposed project. Date: October 9, 2018; September 26, 2019 and September 28, 2020 , by 5:00 PM |
HESI Thrive |
Biden Cancer Initiative | THRIVE is interested in research that will advance our:
|
FUNDING
KEY DATES
|